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723Carotid Artery StentingABSTRACTCarotid artery stenting (CAS) has achieved clinical equipoise with carotid endarterectomy (CEA), as evidenced by 2 large
U.S. randomized clinical trials, multiple pivotal registry trials, and 2 multispecialty guideline documents endorsed by 14
professional societies. The largest randomized trial conducted in patients at average surgical risk of CEA, CREST (Carotid
Revascularization Endarterectomy Versus Stenting Trial) found no difference between CAS and CEA for the combined
endpoint of stroke, death, and myocardial infarction (MI) after 4 years of follow-up. The largest randomized trial
comparing CAS and CEA in patients at increased surgical risk, SAPPHIRE (Stenting and Angioplasty with Protection in
Patients at High Risk for Endarterectomy), looked at 1-year stroke, death, and MI incidence and found no difference in
symptomatic patients, but a signiﬁcantly better outcome in asymptomatic patients for CAS (9.9% vs. 21.5%; p ¼ 0.02).
Given that >70% of carotid revascularization procedures are performed in asymptomatic patients for primary prevention
of stroke, it is incumbent upon clinicians to demonstrate that revascularization has an incremental beneﬁt over highly
effective modern medical therapy alone. (J Am Coll Cardiol 2014;64:722–31) © 2014 by the American College of
Cardiology Foundation.B alloon angioplasty of extracranial carotidartery stenoses to prevent stroke was ﬁrstreported >30 years ago (1). Thereafter, reports
of carotid artery stenting (CAS), with or without
embolic protection devices (EPDs), began to appear
(2,3). CAS was developed to address the need for ca-
rotid revascularization in patients in whom open sur-
gery was either difﬁcult to perform (Fig. 1) or who
were at high risk of complications (Table 1).
CAS may be one of the most studied clinical pro-
cedures in medicine, but one of the primary con-
founders in assessing CAS outcomes has been the
dynamic, evolving nature of the CAS procedure
compared with the mature, stable carotid endarter-
ectomy (CEA) procedure. CAS procedures today pro-
duce more favorable outcomes than those performed
15 years ago (Central Illustration), and the dramatic
improvement can be attributed to improved equip-
ment as well as the increased experience of operators
and endovascular teams. However, clinical growth
and expansion of CAS in the United States face a major
barrier in the conservative reimbursement strategy by
Centers for Medicare & Medicaid Services and com-
mercial third-party payers that severely limit patients’
eligibility for coverage.
NATURAL HISTORY
More than three fourths of a million strokes occur each
year, making it the third leading cause of death in the
United States. Ischemic strokes, which are the most
common, are often caused by atherosclerotic emboli
from the carotid artery or aortic arch or are related to
thromboembolism from the heart chambers.Preventing these cerebrovascular events is a chal-
lenge given the large population of patients affected.
The incidence of asymptomatic extracranial carotid
stenosis ($50%) in persons older than 65 years of age is
estimated to be between 5% and 10%, but less than 1%
have a critical stenosis (>80%) (4). Moreover, whereas
10% to 20% of all strokes arise from atherosclerotic
carotid artery stenosis, most symptoms are due to
carotid artery plaque rupture and only a minority to
carotid artery occlusion. Risk assessment can be
affected by variables such as symptom status, stenosis
severity, existence of plaque ulceration, and the na-
ture of the plaque (lipid rich, sclerotic, homogeneous,
or heterogeneous in composition) (5–9). As stenosis
severity increases, so too does the risk of ipsilateral
stroke in symptomatic patients on medical therapy.
Further complicating the situation: the stenosis
itself often provides few clues to assist in risk
assessment. In the NASCET (North American Symp-
tomatic Carotid Endarterectomy Trial), the 2-year
stroke rate was 22% among those with moderate
(50% to 69%) stenosis and 26% with 70% to 99% ca-
rotid stenosis (10). The asymptomatic patients at
highest risk of stroke are those with severe stenoses
or those with progressive carotid narrowing (4,6).
Paradoxically, the very tightest symptomatic lesions,
near occlusions of the carotid artery, do not appear to
beneﬁt from CEA (11,12). On the other hand, men tend
to beneﬁt more from CEA than women, particularly
men with moderately severe (50% to 69%) stenosis
and those with asymptomatic carotid lesions.
Using symptoms to guide clinical decision making
will miss many high-risk patients. The annual risk of
stroke is between <1.0% and 4.3% for asymptomatic
FIGUR
Angiog
interna
TABLE 1 Features Associated With High Risk of
Carotid Endarterectomy
Medical Comorbidity Anatomic Criteria
Elderly (>75/80 yrs) Surgically inaccessible
lesions
Congestive heart failure (NYHA
functional class III/IV)
At or above C2
Unstable angina (CCS III/IV) Below the clavicle
ABBR EV I A T I ON S
AND ACRONYMS
CAS = carotid artery stenting
CEA = carotid endarterectomy
EPD = embolic protection
device
MI = myocardial infarction
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724patients with $50% stenosis of the carotid
artery (6,7,13,14). More importantly, however,
is evidence that the majority (w80%) of
strokes have no recognizable warning symp-
toms. Therefore, as difﬁcult as it might be,
identifying which asymptomatic patients
with CAS are at high risk of stroke is important
(6,15,16).CAD with $2 vessels $70% stenosis Ipsilateral neck irradiation
Recent myocardial infarction
(#30 days)
Spinal immobility of the neck
Planned open heart surgery (#30 days) Contralateral carotid artery
occlusion
Ejection fraction #30% Laryngeal palsy
Severe pulmonary disease (COPD) Tracheostoma
Severe renal disease Previous ipsilateral CEA or
neck surgery
C2 ¼ the second cervical spine vertebral body; CAD ¼ coronary artery disease;
CCS ¼ Canadian Cardiovascular Society; CEA ¼ carotid endarterectomy; COPD ¼
chronic obstructive pulmonary disease; NYHA ¼ New York Heart Association.INDICATIONS FOR CAROTID
REVASCULARIZATION
Determining who may beneﬁt from CEA revasculari-
zation versus medical therapy for stroke prevention
is complicated by the paucity of contemporary com-
parative data. Indeed, the multiple randomized trials
validating CEA as superior to medical therapy were
largely conducted before the widespread adoption
of modern antiatherosclerotic medical therapy (12).
Evidence supporting our current pharmacological
armamentarium of antihypertensive medications, an-
tiplatelet therapies, cholesterol-lowering drugs, and
smoking cessation programs is much more robust (17)
than during the 1990s when CEA was being compared
with aspirin alone for stroke prevention in sym-
ptomatic (10,12) and asymptomatic (18–20) patients.
SYMPTOMATIC CAROTID ARTERY PLAQUE. Vari-
ability and unreliability in the reporting of surgicalE 1 Carotid Artery Stent Procedure
ram of baseline (left) and ﬁnal result (right) of very tight
l carotid artery stenosis (arrow).results continue to make interpretation and com-
parison of database studies problematic. In a 1996
meta-analysis of CEA in symptomatic patients, the
strongest predictor of 30-day stroke or death turned
out to be who performed the postoperative assess-
ment (21). When a neurologist evaluated post-
operative CEA patients, the risk of 30-day stroke
and death was 7.7%; however, when a surgeon who
was the sole author of a paper performed the evalu-
ation, the risk was reported as 2.3%. The American
Heart Association expert consensus panel suggested
that the perioperative risk of stroke and death should
not exceed 3% for asymptomatic patients, 6% for
symptomatic patients, or 10% for repeat CEA (22).
SYMPTOMATIC HIGH SURGICAL RISK. The in-
dications for CAS in symptomatic patients depend on
whether they are at high risk of surgical complica-
tions of CEA (Table 1). The multicenter SAPPHIRE
(Stenting and Angioplasty with Protection in Patients
at High Risk for Endarterectomy) trial randomized
patients at increased risk of surgical complications
to CEA (n ¼ 167) or CAS (n ¼ 167) (23). At 1 year, the
results clearly demonstrated noninferiority (CAS,
12.2%, CEA, 20.1%; p ¼ 0.004 for noninferiority)
across the entire cohort for major adverse events.
These included the cumulative incidence of death,
stroke, or myocardial infarction (MI) within 30 days
after the procedure or death or ipsilateral stroke be-
tween 31 days and 1 year. Symptomatic patients
demonstrated no differences between the treatment
groups for major adverse events at 30 days (CAS, 2.1%
vs. CEA, 9.3%, p ¼ 0.95) and 1 year (CAS, 16.3% vs.
CEA, 20.0%, p ¼ 0.58) (Central Illustration) (24). The
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Comparing CAS and CAE Results In Low Surgical Risk Patients37
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CENTRAL ILLUSTRATION Carotid Artery Stent Outcomes
(A) Comparing carotid artery stent (CAS) and carotid endarterectomy (CAE) results in high
surgical risk symptomatic patients. (B) Comparing CAS and CAE results in average surgical risk
patients. (C)CASresultsshowingan improvingtrend inhighsurgical riskpatients (2003to2012).
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725durability of CAS relative to CEA was maintained out
to 3 years of follow-up (25).
The current multisocietal guidelines recommend
CAS as an alternative to CEA for treating symptomatic
patients at increased risk of complications of CEA, if
performed by an experienced operator and an expe-
rienced team, with expected 30-day morbidity and
mortality outcomes similar to those observed in
clinical trials (4% to 6%) (Table 2) (26,27). Currently,
symptomatic patients with $70% carotid artery ste-
nosis who are at high risk of CEA complications
constitute the group eligible for CAS coverage if they
cannot be enrolled in an U.S. Food and Drug Admin-
istration–sanctioned clinical trial.
SYMPTOMATIC AVERAGE SURGICAL RISK. There
have been 3 international, randomized, controlled
trials comparing CEA and CAS: SPACE (Stent-
Supported Percutaneous Angioplasty of the Carotid
Artery versus Endarterectomy) (28), EVA-3S (End-
arterectomy Versus Angioplasty in Patients With
Symptomatic Severe Carotid Stenosis) (29), and
ICSS (International Carotid Stenting Study) (30)—all
with seriously ﬂawed designs: no quality control
for CAS operators and no required use of an
EPD, the standard of care in the United States (31).
These shortcomings translated to operator inexpe-
rience and CAS performed by trainees to accelerate
enrollment. Challenged by the additional com-
plexity of using an EPD with CAS, many operators
abandoned this important step, sacriﬁcing patient
safety.
The largest trial comparing CAS and CEA in
average surgical risk patients, CREST (Carotid
Revascularization Endarterectomy Versus Stenting
Trial) enrolled 1,321 (53%) symptomatic patients and
found no difference for the primary endpoint of
stroke, MI, or death from any cause during the peri-
procedural period or any ipsilateral stroke within 4
years after randomization between CEA (8.4  1.2%)
and CAS (8.6  1.1%) (27). When focusing only
on incidence of stroke (e.g., periprocedural stroke
and/or post-procedural ipsilateral stroke), both pro-
cedures produced similar rates at 4 years (CAS, 7.6 
1.1% vs. CEA, 6.4  1.1%; p ¼ 0.25) (Central
Illustration).
CREST required low-volume CAS operators to
qualify for trial participation by treating as many as
20 “lead-in” patients, a unique and critical step when
attempting to compare the evolving CAS procedure
with a mature, stable procedure such as CEA. At 1,565
in total, the number of CREST lead-in patients tripled
that enrolled in EVA-3S and was 25% more than the
SPACE patient population. The lead-in phase results
from those relatively inexperienced CAS operatorsunderscore the importance of experience and further
demonstrate the ﬂaws in the European trials. Vas-
cular surgeons, the most inexperienced of the clinical
participants, had signiﬁcantly worse outcomes than
TABLE 2 Multidisciplinary Carotid Stent Guidelines
Indication Recommendation Level of Evidence Guideline (Ref. #)
Symptomatic high surgical risk: Among patients with symptomatic severe stenosis
(>70%) in whom the stenosis is difﬁcult to access surgically, medical
conditions are present that greatly increase the risk of surgery, or when
other speciﬁc circumstances exist, such as radiation-induced stenosis or
restenosis after CEA, CAS may be considered when performed by an
experienced operator
Class IIa B American Heart Association and
American Stroke Association
guideline (26)
It is reasonable to choose CAS over CEA when revascularization is indicated in
patients with neck anatomy unfavorable for arterial surgery
Class IIa B Multisociety guideline (27)
Symptomatic average surgical risk
CAS is indicated as an alternative to CEA for symptomatic patients at average or
low risk of complications associated with endovascular intervention when
the diameter of the lumen of the internal carotid artery is reduced by >70%
as documented by noninvasive imaging or >50% as documented by catheter
angiography and the anticipated rate of periprocedural stroke or mortality
is <6%.
Class I B Multisociety guideline (27)
CAS is indicated as an alternative to CEA for symptomatic patients at average or
low risk of complications associated with endovascular intervention when
the diameter of the lumen of the internal carotid artery is reduced by >70%
by noninvasive imaging or >50% by catheter angiography
Class I B American Heart Association and
American Stroke Association
guideline (26)
Asymptomatic high surgical risk patients
Selection of asymptomatic patients for carotid revascularization should be
guided by an assessment of comorbid conditions, life expectancy, and other
individual factors and should include a thorough discussion of the risks and
beneﬁts of the procedure with an understanding of patient preferences
Class I C Multisociety guideline (27)
It is reasonable to choose CAS over CEA when revascularization is indicated in
patients with neck anatomy unfavorable for arterial surgery
Class IIa B Multisociety guideline (27)
Asymptomatic average surgical risk patients
Prophylactic CAS might be considered in highly selected patients with
asymptomatic carotid stenosis (minimum 60% by angiography, 70% by
validated Doppler ultrasound), but its effectiveness compared with medical
therapy alone in this situation is not well established
Class IIb B Multisociety guideline (27)
Multisociety guideline endorsed by the American College of Cardiology, American Heart Association, American Stroke Association, American Academy Neurology, American Association
Neuroscience, American Association of Neurological Surgeons and Nurses, American College Radiology, American Society of Neuroradiology, Society of Cardiovascular Angiography
Interventions, Society of Intervention Radiology, Society of Vascular Medicine, Society of Vascular Surgery.
Abbreviations as in Table 1.
IR [OR = 1.66; 95% CI: 0.89 to 3.08] 
INR [OR = 0.39; 95% CI: 0.13 to 1.15]
Cardiology
Vasc Surg [OR = 2.05; 95% CI: 1.18 to 3.56]
0 1
p < 0.014
2 3 4
Neuro Surg [OR = 1.66; 95% CI: 0.66 to 4.16]
FIGURE 2 Carotid Artery Stent Outcomes by Specialty
CREST lead-in outcomes by physician specialty. Reprinted
with permission from White (70). CI ¼ conﬁdence interval;
INR ¼ international normalized ratio; IR ¼ interventional
radiology; Neuro Surg ¼ neurological surgeon; OR ¼ odds ratio;
Vasc Surg ¼ vascular surgeon.
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726did cardiologists or radiologists (32) (Fig. 2). The
difference in outcomes based on experience is
magniﬁed in the most complex patients: compare the
30-day stroke and death rates for the CREST lead-in
elderly (>80 years) cohort of 12.1% (33) to 5.0% in
similar patients treated by more experienced opera-
tors (34).
Multisocietal guidelines recommend CAS (class I)
as an alternative to CEA for symptomatic patients at
average risk of complications associated with endo-
vascular intervention depending on the lumen dia-
meter of the internal carotid artery and the anticipated
rate of periprocedural stroke or mortality (Table 2)
(26,27).
ASYMPTOMATIC CAROTID ARTERY PLAQUE. The
strongest evidence favoring revascularization in
asymptomatic patients comes from randomized clin-
ical trials, ACAS (Asymptomatic Carotid Atheroscle-
rosis Study) (35) and ACST (Asymptomatic Carotid
Surgery Trial) (21), that were performed before the
widespread availability of modern multimodality
medical therapy, particularly statins. The most con-
servative estimate is that the current incidence ofan asymptomatic carotid stenosis leading to a stroke
is <1% per year; if true, it is difﬁcult to make the
case that revascularization would provide an addi-
tional beneﬁt (36). This has led to a proposal for
30% AsymptomaticPatients
Randomized Stent
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FIGURE 3 Carotid Endarterectomy Versus Carotid Artery Stent in
Asymptomatic Patients in the SAPPHIRE trial
Cumulative percentage of major adverse events (MAE) in asymptomatic randomized
patients at 360 days for the SAPPHIRE (Stenting and Angioplasty with Protection in
Patients at High Risk for Endarterectomy) trial (24).
TABLE 3 Features Suggested to Increase the Risk of a Carotid Stent Procedure
Medical Comorbidity Anatomic Criteria Procedural Factor
Elderly (>75/80 yrs) Type III aortic arch Inexperienced operator/center
Symptom status Vessel tortuosity EPD not used
Bleeding risk/hypercoagulable
state
Heavy calciﬁcation Lack of femoral access
Severe aortic stenosis Lesion related
thrombus
Time delay to perform procedure
from onset of symptoms
Chronic kidney disease Echolucent plaque
Decreased cerebral reserve Aortic arch atheroma
EPD ¼ embolic protection device.
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727a CREST-2 trial, which will randomize asymptomatic
patients with signiﬁcant carotid lesions to revascu-
larization (CEA or CAS) versus multimodality medical
therapy.
Pending the outcome of new trials, clinicians should
continue to consider revascularization of asymptom-
atic patients with signiﬁcant carotid artery steno-
sis (>60%), such as before elective heart surgery, to
protect the brain from hypotension-related hypo-
perfusion and in patients with rapidly progressing
lesions, contralateral carotid occlusions, or ulcerated
or other high-risk plaque features that increase stroke
incidence. Because most strokes occur without warn-
ing, knowing the informed asymptomatic patient’s
preferences for revascularization (CAS or CEA) may
help get them care more quickly with an appropriate
experienced team.
ASYMPTOMATIC HIGH SURGICAL RISK. In this pa-
tient population, strong data from SAPPHIRE (23) and
multiple registry trials demonstrated excellent peri-
procedural outcomes with very durable results for
CAS over CEA. Although the 30-day periprocedural
incidence of death, stroke, or MI in SAPPHIRE was
similar between the groups (CAS, 5.4% vs. CEA,
10.2%; p ¼ 0.20), CAS proved superior to CEA for the
1-year primary endpoint (30-day incidence of death,
stroke, or MI plus death or ipsilateral stroke between
31 days and 1 year) in high surgical risk asymptomatic
patients (9.9% vs. 21.5%; p ¼ 0.02) (Fig. 3) (24). The
beneﬁts of CAS relative to CEA were maintained for
up to 3 years (25).
According to guidelines (27), selection of asymp-
tomatic patients for carotid revascularization should
be guided by an assessment of the comorbid and
anatomic features, with the patients’ preferences
taken into consideration (class I). For patients with
unfavorable anatomy for surgery, the guideline rec-
ommends CAS over CEA (Class IIa) (Table 2).
ASYMPTOMATIC AVERAGE SURGICAL RISK. For
asymptomatic patients at average risk of complica-
tions with CEA, CREST provided evidence of equi-
poise between CEA and CAS for the primary endpoint
of stroke, MI, or death from any cause during the
periprocedural period or any ipsilateral stroke within
4 years after randomization (CAS, 5.6  1.0% vs. CEA,
4.9  1.0%; p ¼ 0.56); there was no signiﬁcant dif-
ference for the individual outcome of stroke (CAS, 4.5
 0.9% vs. CEA, 2.7  0.8%; p ¼ 0.07) (37).
The multisocietal guideline (27) recommends consid-
ering CAS in asymptomatic average-risk patients
(Class IIb) but cautions that the beneﬁt of revascu-
larization versus medical therapy is not well estab-
lished (Table 2).CAS PROCEDURAL RISK ASSESSMENT
The solid information that clinicians possess re-
garding criteria and conditions that increase patient
risk of CEA complications should inﬂuence treatment
recommendations given to patients. Less well un-
derstood are factors that place patients at increased
risk of complications from CAS (38). CAS procedural
risk assessment should encompass the patient’s
medical comorbidities, such as symptom status or
age, anatomic characteristics (e.g., type III aortic arch
or severe carotid artery tortuosity), and ﬁnally pro-
cedural factors such as operator and team experience
(Table 3).
Experts agree that in patients with anatomic fea-
tures that prolong catheter manipulation or make
crossing a carotid stenosis, EPD use, or stent deploy-
ment difﬁcult, CAS should be avoided if possible.
Other characteristics that make endovascular therapy
trickier or riskier, prompting consideration of CEA,
Touze et al.
(Stroke and Death)
RR = 0.57 (95% CI: 0.43 to 0.76)
Pooled Results for EPDs and Carotid Stenting
EPD Reduces Risk EPD Increases Risk
0.1 1 10
RR = 0.62 (95% CI: 0.54 to 0.72)
Garg et al.
(Total Stroke Rate)
FIGURE 4 Utility of Embolic Protection Devices in
Carotid Artery Stent
Summary and meta-analysis data supporting the use of
embolic protection device (39,40). CI ¼ conﬁdence interval;
EPD ¼ embolic protection device; RR ¼ relative risk.
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728include 1) compromised vascular access, 2) severe
iodinated contrast reactions, and 3) chronic kidney
disease, which puts the patient at risk of contrast-
induced nephropathy. In the end, operator and team
experience may be the most important factor in
determining which patients are better suited for CEA
or CAS.
OPTIMIZING CAROTID STENTING
Step 1 in enhancing a carotid stent program is focused
patient selection to maximize the likelihood of patient
beneﬁt and minimize periprocedural risk. For
example, symptomatic patients have more to gain
from a successful revascularization procedure than do
asymptomatic patients. Patients who require revas-
cularization but are at increased risk of CEA compli-
cations should be preferentially treated with CAS and
vice versa, keeping operator and team experience,
with independent adjudication of outcomes for CAS
and CEA, squarely in mind. Early in their learning
curve, less experienced operators should be selecting
low-risk CAS patients, such as those with recurrent
stenosis after CEA, working up to more complex pa-
tients, preferably partnering with mentors who can
guide them as they master these techniques.
EMBOLIC PROTECTION DEVICES. Because of the
very low incidence of stroke complicating CAS,
demonstrating clinical beneﬁt for any embolic pro-
tection device requires aggregating data into sum-
mary reports (39) and meta-analyses (40) (Fig. 4). The
risk-to-beneﬁt assessment intuitively favors using a
protection device. One simply has to retrieve a ﬁlter
full of debris to realize the empirical beneﬁts relative
to the rare complications associated with an EPD.
However, EPD use complicates and prolongs CAS
procedures, particularly for inexperienced operators
(41). In multiple small (<100 patients), randomized,
controlled trials comparing EPDs that produce very
low clinical event rates, reliance on surrogate end-
points (e.g., Doppler detection of embolic signals)
blurs the direct relationship to clinical events (42–47).
This provides little evidence to support recommen-
dations regarding the superiority of speciﬁc devices.
At the present time, optimal practice should include
the use of an EPD, one that the operator is most
comfortable using.
CHOICE OF CAROTID STENT. Stent type (open vs.
closed cell) does not appear to affect the occurrence
of CAS complications, but confounding any non-
randomized assessment of stent type is that carotid
lesion morphology drives stent choice. Typically
more ﬂexible and conformable, open-cell stents are
preferred in more complex angulated lesions, whichare more likely to result in complications, whereas
closed-cell stents, which offer more complete surface
coverage, are preferred in straighter, less complex
lesion segments. This introduces a selection bias that
favors closed cell stents. Although several authors
have reported an association of CAS complications
with open-cell stents (48), particularly in symptom-
atic patients (49) and those with echolucent plaques
(50), a large series failed to show any relationship
between the stent type and the occurrence of CAS
complications (51), which was conﬁrmed in a ran-
domized, controlled trial (52).
BASELINE AND COMPLETION INTRACEREBRAL
ANGIOGRAPHY. Before a carotid stent procedure, the
intracranial vascular anatomy, including the circle of
Willis, should be imaged by angiography, as knowl-
edge of the baseline anatomy becomes very important
if complications occur. Likewise, completion angiog-
raphy, visualizing the vascular segment proximal
to the stented segment and the distal intracranial
vascular anatomy in orthogonal views, is strongly re-
commended to conﬁrm the presence of major intra-
cerebral vascular branches.
PRE- AND POST-PROCEDURAL BALLOON DILATION.
Clinicians now routinely pre-dilate CAS with an EPD
in place. The balloon is sized conservatively (2.5 to
4.0 mm) and inﬂated until fully expanded. If hemo-
dynamic compromise or severe bradycardia is associ-
ated with stimulating the carotid body, it will
manifest during pre-dilation and can be treated with
appropriate volume replacement, vasopressors, and
vagolytic pharmacology before stent deployment.
With the low CAS restenosis rate, post-stent dila-
tion generally is avoided; instead, clinicians allow the
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729self-expanding carotid stent to gradually reach its
nominal diameter. Several studies have demon-
strated signiﬁcant bursts in Doppler signals consis-
tent with showers of emboli with post-stent dilation,
and the procedure does not appear to lower reste-
nosis rates.
CONCLUSIONS
In patients at increased risk of complications of CEA,
data from SAPPHIRE and numerous pivotal registries
(53–66) support CAS as an alternative to CEA. For both
symptomatic and asymptomatic patients at average
risk of CEA complications, the largest randomized
clinical trial to date (CREST) conﬁrms equipoise for
CAS and CEA when these procedures are performed
by experienced operators and teams. In recognition
of this extensive evidence base, both an expert
consensus document (67) and various guidelines
endorsed by major stakeholder professional societies
recommend that CAS be considered an alternative to
CEA in average surgical risk patients (Table 2) (26,27).
Despite the lack of signiﬁcant difference in
the combined endpoint in CREST and the overall
occurrence of stroke among the symptomatic and
asymptomatic groups out to 4 years, patients in the
CAS group experienced an excess of periprocedural
minor strokes and the CEA arm an excess of MI
(68,69). The occurrence of either stroke or MI was
associated with a signiﬁcant 2- to 3-fold risk of mor-
tality. Surgeons are fond of talking about “troponin
leaks” as if there is no consequence, but the CREST
investigators found that patients with isolated
troponin elevations had more than a 3-fold increase
in mortality (hazard ratio: 3.57; 95% conﬁdence in-
terval: 1.46 to 8.68) (69). When planning revascular-
ization, one should select a revascularization strategy
that will minimize both stroke and MI in individual
patients.
Physicians should discuss available treatment op-
tions, including revascularization, with patients atrisk or stroke from carotid artery disease. Uncertainty
remains regarding the value proposition for revascu-
larization (either CEA or CAS) in asymptomatic pa-
tients as a strategy to prevent stroke in 2014
(35); thus, investigations continue to identify subsets
of patients with carotid plaque at higher risk of
causing strokes. A point to consider when weighing
revascularization of an asymptomatic patient is
that as the population lives longer, patients enjoy a
cumulative beneﬁt of freedom from stroke that en-
sues if the revascularization procedure is uncompli-
cated. Less clear, however, is the relative beneﬁt of
revascularization in asymptomatic patients over the
long term compared with multifactorial medical
therapy, including statins.
No one can know exactly what the future holds for
carotid stenting, but one reasonably safe bet is that
less invasive CAS will eventually replace the more
invasive CEA in patients requiring revascularization.
Expect this change to be largely driven by younger,
endovascularly trained vascular surgeons who have
no ingrained loyalty to CEA and will willingly accept
CAS. Another prudent prediction is that far fewer
asymptomatic patients will undergo revasculariza-
tion to prevent stroke as multimodality medical
therapy continues to improve. At some point, the
evidence supporting CAS noninferiority to CEA will
switch on the light bulbs for government regulators
and third-party payers to expand reimbursement of
CAS to achieve equivalency with CEA. This expansion
of CAS cases, as a percentage of total carotid revas-
cularization procedures, will drive further technical
enhancements and procedural evolution that will
result in continued improvements in CAS safety and
efﬁcacy.
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